HNO-Heme Adducts
Interest in HNO in the Farmer laboratory originated from efforts to model reductive heme-based catalysis involved in the global nitrogen cycle (Scheme 1). 1 The six-electron reduction of nitrite to ammonia can be driven by a single enzyme, as in assimilatory nitrite reductases, or can occur stepwise via dissimilatory enzymes, which take nitrite to nitric oxide (NO), N 2 O, and N 2 . Heme nitroxyl intermediates have been postulated in these NO x reductions, as indicated by the dotted line in Scheme 1.
A common mechanistic question in enzymatic reduction of nitrogen oxides is whether a nitroxyl intermediate is generated by sequential electron transfer or by a two-electron process such as hydride transfer (Scheme 2).
2,3 The contention is that a ferrous nitrosyl intermediate (Fe II NO) if transiently formed would be stable and difficult to reduce, thus acting as a catalytic dead end. For example, the singleelectron reduction of NO-Fe II Mb occurs at ca. -650 mV vs NHE, 4 which is at the edge of the biological reduction range. 5 An authentic nitroxyl intermediate has been observed during turnover of the fungal NO reductase cytochrome P450nor. 6 In its catalytic cycle, a ferric nitrosyl complex of P450nor is reduced by NADH to generate an intermediate (λ max at 444 nm) that subsequently reacts with NO to give ferric heme and N 2 O, which is the nitrogen product of the HNO self-consumption pathway. 7 17 resonance Raman, and X-ray absorption spectroscopy/X-ray absorption near-edge structure analysis. 18 The 1 H NMR spectrum is particularly diagnostic, with characteristic signals for HNO at 14.9 ppm and for the methyl group of Val68 at -2.5 ppm.
In Figure S8 in the Supporting Information and eqs 1 and 3). This lends credence to the supposition that NO-Fe II is avoided during catalytic turnover in P450nor. This also implies that free HNO, or an HNO-releasing species, is generated upon reduction of nitrite by borohydride in aqueous solution.
A complication is that the within a protein pocket will produce two different diastereomers. To examine this hypothesis, a sample of apomyoglobin was reconstituted with the iron complex of symmetrical 2,4-dimethyldeuteroporphyrin (Scheme 3), and its HNO adduct was prepared by the nitrite/borohydride method. The resulting 1 H NMR spectrum of the low-concentration product solution yields single HNO and valine resonances, consistent with the heme orientational hypothesis. Further 2D NMR studies are underway to better characterize the structural differences of these diastereomeric forms.
To better understand how HNO adducts are formed in the nitrite/borohydride procedure, the three reactants were combined sequentially in several ways (see part S1a in the Supporting Information). HNO-Fe II Mb was formed when either met-or deoxymyoglobin was reacted with nitrite and borohydride in any addition order. One plausible reaction of hydride with nitrite is the generation of free HNO, which might then be trapped by Fe II Mb (eqs 4 and 5). Substitution of dithionite by borohydride yielded a product solution with a similar signal but at less than 5% of the intensity, suggesting that the majority of the product was the diamagnetic NO --Fe II MGD species. Both reactions clearly suggest that HNO or an HNO-releasing species is formed in the presence of nitrite/borohydride.
The versatility of using borohydride to generate HNO adducts in aqueous solutions was investigated with nitroprusside 3-complex. Thus, use of borohydride provides a convenient route to HNO complexes in a one-flask reaction using simple chemical reagents rather than the laborious stepwise procedures previously utilized.
Acidity/Basicity of HNO-Metal Adducts. In 1970, the pK a of HNO in solution was estimated at 4.7, but more recent work showed the value to be ∼11.5.
28,29 Coordination to a cationic metal ion should lower the pK a of HNO, but this has been difficult to characterize in known smallmolecule complexes. As mentioned above, Olabe and coworkers reported the generation of an HNO 27 The adduct is unstable at pH 10; however, lowering the pH to 7 increases the stability such that an HNO resonance can be observed at 20.02 ppm (Figure 3 ). Analysis of the 1 H NMR signal during pH titration indicated a pK a value of 7.7.
For HNO-Fe II Mb, a change in the HNO resonance in the 1 H NMR spectrum was not observed from pH 6.5 to 10, suggesting that the pK a is well above the range of the well-known acid-alkaline transition for Fe III Mb. 
Protein samples at higher pH are unstable over time and unsuitable for NMR studies. 30 However, electronic absorption spectra of dilute samples of HNO-Fe II Mb at high pH do show characterizable changes. As seen in Figure 4 , the high-energy band blue shifts at pHs above 11, whereas changes were not evident in the spectra of NO-Fe II Mb or Fe II Mb. This suggests that the pK a of the HNO adduct is above 10 and likely close to 11.
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For heme-based oxidoreductases and other metalloproteins, the influence of hydrogen-bonding residues within an active site is often crucial to the mechanism of action. A recent DFT analysis of resonance Raman data on a variety of NO adducts of heme proteins led Xu and Spiro to postulate a differential effect of hydrogen bonding to the nitrogen or oxygen atoms of the coordinated nitrosyl.
32 Whereas hydrogen bonding to the oxygen atom strengthens back-bonding with the metal, hydrogen bonding to the nitrogen atom weakens both the Fe-N and N-O bonds and primes the nitrosyl adduct for reduction to the HNO-Fe II Mb state. Such hydrogenbonding interactions would likely play an important role in NO x -reducing enzymes, such as several heme-based nitrite reductases and the P450 and binuclear iron nitric oxide reductases.
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Evidence for such interactions is observed by analysis of the deuterium exchange in HNO-Fe II Mb, which can be quantified by integration of the HNO peak at 14.9 ppm against that of the methyl group of Val68 at -2.5 ppm in the 1 H NMR spectrum ( Figure 5 ). The rate of H/D exchange of HNO in HNO-Fe II Mb is also quite distinctive. The exchange rate is slow at physiological pH (t 1/2 ∼ 5.5 h at pH 8) but increases significantly under more alkaline conditions (t 1/2 ∼16 or 9 min at pH 9 or 10, respectively). This behavior may be linked to changes in hydrogen-bonding interactions with the distal His64, which hydrogen bonds to the oxygen atom of the HNO adduct.
Previous NMR analysis of HNO-Fe II Mb found few differences between spectra collected at pH 7 or 10; notable exceptions were resonances assigned to N-H protons on the proximal His93, which shifted from 9.32 to 9.68 ppm, and that of the distal His64, which is at 8.11 ppm at pH 8.5 but is not observed at pH 10. Loss of this distal His64 hydrogen-bonding interaction with the HNO adduct would explain the abrupt change in H/D exchange in the same pH region. As illustrated in Scheme 4, the His64 hydrogen-bonding interaction promotes charge buildup on the HNO moiety via back-bonding with the electron-rich Fe 11 Loss of this chargestabilizing interaction at the oxygen atom may result in a lowering of the pK a of the nitrogen-bound proton and thus an increase in H/D exchange. A reviewer suggests that deprotonation of His64 may open access to the distal pocket, thus facilitating H/D exchange. 34 HNO as an O 2 Analogue. HNO is the simplest analogue of alkylnitroso compounds (RNO), which have long been known to bind to ferrous heme proteins.
35, 36 Mansuy and co-workers were the first to describe the binding of RNO compounds to Mb and Hb, 37 as well as to make the analogy of RNO binding to that of O 2 . 38 Although quite rare, a small number of well-characterized organometallic HNO complexes have been identified. Several routes to HNO-metal complexes have been reported, including the direct reduction of a metal nitrosyl, two-electron oxidation of a metal-hydroxylamine adduct, 39 ,40 the insertion of NO into a metal hydride bond, 41, 42 and the addition of hydride to a metal-bound NO. 43 47 other oxygen-binding proteins such as hemoglobin (Hb), leghemoglobin (legHb), and an H 2 Sbinding hemoglobin from the clam L. pectinata were shown to readily trap free HNO in solution to form HNO adducts in good yield as characterized by peaks at ca. 15 ppm in the 1 H NMR spectra. Peptidic protons in strong hydrogen bonds may also have downfield resonances, as shown in Figure 6 for the HNO adduct of Hb, which has distinctive downfield resonances at ca. 12-13 ppm because of hydrogen bonds at the R and β subunit interface. Therefore, a key proof is to generate a labeled H 15 NO adduct because the resulting HNO resonance will be split into a doublet by the 15 N nuclear spin.
15
N-labeled samples also allow heteronuclear single quantum coherence (HSQC) spectra to be readily obtained, which provide characterization of the 15 N chemical shifts, as demonstrated in Figure 6 .
The affinity of the oxygen-binding heme proteins for both HNO and O 2 also suggests that HNO might bind and/or inhibit nonheme oxygenases. For instance, HNO precursors inhibit the pigmentation of melanogenic cells, 48 which depend on the activity of tyrosinase, an oxygenase that binds O 2 between two copper centers. 49 HNO in Mammals. Interest in HNO in mammalian systems dates to the early 1980s when vasodilation was determined to be actively mediated by an unidentified species 50 designated as the endothelium-derived relaxing factor (EDRF). 51 The EDRF was subsequently determined to be NO, but the identification process led to comparisons of the effects of NO and HNO donors in vasoactive assays. Such experiments were the genesis of the current expanding interest in the pharmacological effects of HNO donors. Consequently, analysis of the aqueous chemistry as well as the biochemistry of HNO has arisen in order to identify the chemical origins of the pharmacological effects. The chemical reactions of HNO under physiological conditions and their consequences in mammalian biology are beyond the scope of this review and have been presented recently elsewhere. 46, [52] [53] [54] Other recent research has focused on the identification of mechanisms and markers of HNO biosynthesis and on the production of novel HNO donors with properties tailored for clinical use. Donor compounds are necessary not only for facile or controlled delivery but also because of the self-consumption of HNO via irreversible dehydration of the dimer. 55, 56 Donors of HNO have also been recently reviewed. 57, 58 About the same time that the vasoactivity of HNO was observed, Nagasawa and colleagues determined that cyanamide (H 2 NCN), an alcohol deterrent used in Europe, Canada, and Japan for the clinical treatment of chronic alcoholism, is bioactivated by mitochondrial catalase to produce HNO. [59] [60] [61] Cyanamide is a potent inhibitor of aldehyde dehydrogenase (AlDH), which catalyzes the conversion of the acetaldehyde generated in the oxidative metabolism of ethanol to acetate. Inhibition of AlDH results in acetaldehydemia, provoking an unpleasant physiological response and ostensibly leading to alcohol avoidance. The inhibition mechanism involves association of HNO with an active-site thiol. 62 These results provided the first clinical application of an HNO donor and demonstrated that HNO donors could be administered safely and with effect to humans. Consequently, a large series of prodrugs of HNO were developed to elicit this response in vivo (see, for instance, refs 63-68). Additionally, thiols were shown to be major targets of HNO. Subsequently, the interaction of HNO with thiols was shown to lead to reversible (eq 11) and potentially irreversible (eq 12) modifications, depending on the availability of a second thiol to bind to the N-hydroxysulfenamide (RSNHOH) intermediate (eq 10). [69] [70] [71] [72] [73] RSH þ HNO f RSNHOH ð10Þ
That protein thiols are able to be modified by HNO donors despite the presence of high concentrations of low-molecular-weight thiols such as glutathione (GSH) has now been shown in a number of systems. [74] [75] [76] [77] [78] The mechanism by which HNO escapes scavenging by GSH is not entirely understood but may relate to its hydrophobicity or to the unique properties of protein thiols.
In a somewhat later study, Wink and co-workers demonstrated that an HNO donor (Angeli's salt) elicited significant cytotoxicty toward lung fibroblasts compared to NO donors. 79 This cytotoxicty is dependent upon an aerobic environment, is exacerbated by chemical depletion of cellular GSH, and is induced, in part, by doublestranded DNA breaks and base oxidation. [79] [80] [81] [82] [83] Moreover, this comparative analysis provided the first indication that HNO could affect cellular functions by altering the redox status of the cell in a manner unique from that of NO. Although HNO is capable of inducing oxidative stress, it can also act as an antioxidant via facile hydrogen-atom donation to oxidizing radical species (akin to tocopherol) and subsequent generation of NO, which is an established antioxidant. 84 Significantly, the studies demonstrating the prooxidant effects were performed at high levels of HNO, whereas the antioxidant properties were observed at much lower concentrations.
Later collaborative comparisons demonstrated that the in vitro toxicity of HNO could be replicated in vivo in a model of ischemia-reperfusion injury in rabbits in contrast to NO, which proved to be protective in the same model. 85 Importantly, a subsequent study showed that HNO could be protective toward reperfusion injury if administered prior to the ischemic event. 86 Similar O 2 -dependent responses to HNO were observed in neuronal channel response. 87 Together, these studies led to examination of the reaction of HNO with O 2 , but the product has yet to be identified; [79] [80] [81] [82] [83] [88] [89] [90] for further discussion of this reaction, see ref 52 . Significantly, the autoxidation of HNO is generally too slow (10 3 M -1 s -1 ) to be of kinetic consequence in many biological systems, particularly at pharmacological levels of HNO. 91, 92 Furthermore, a number of comparisons of HNO and NO donors have now appeared in the literature (reviewed in refs 52, 53, 91, and 93-97 ) and nearly universally demonstrate that the physiological properties of HNO and NO are discrete.
Perhaps most importantly, analyses by Wink and colleagues led to intensive investigation of the cardiovascular properties of HNO in dogs (reviewed in refs 53 and 93). HNO was found to enhance myocardial contractility even in failing hearts. 98, 99 As such, HNO donors may act as a novel class of vasodilators and treatments for heart failure. 100 This discovery substantially increased interest in HNO and led to an accelerated publication rate. Ensuing analyses demonstrated that HNO targets key regulators of normal myocyte contractile function and increases the sensitivity of myofilaments to calcium in a thiol-sensitive manner. [101] [102] [103] During their cardiovascular studies, Paolocci and colleagues 98 determined that the vascular effects of HNO in dogs were limited to the venous side of the circulatory system, unlike NO donors, which are systemic hypotensive agents. In vascular smooth muscle, NO leads to dilation by binding to the regulatory ferrous heme of soluble guanylyl cyclase (sGC), which increases the rate of conversion of GTP to cGMP. The strong trans effect of NO induces cleavage of the proximal histidine upon binding, leading to an activating conformational change (Scheme 5). The observation that infusion of HNO donors did not lead to elevated cGMP levels in plasma both indicated that HNO and NO do not interconvert in blood and renewed interest in the vasoactive mechanisms of HNO. 91 Several HNO donors have been observed to induce vasorelaxation in vivo or in rodent arterial/aortic ring assays. 63, [104] [105] [106] These results instigated further examination of the effects of HNO donors on sGC function, usually by measurement of the cGMP levels or determination of the vasorelaxive potency in the presence of sGC inhibitors. 63, 104, [106] [107] [108] [109] [110] [111] [112] [113] [114] The question of the direct activation of sGC was addressed by Dierks and Burstyn, 115 who exposed partially purified bovine lung sGC to donors of NO, NO þ , and HNO and observed enhanced cGMP formation only upon the introduction of NO. This finding, in addition to earlier examinations of the reaction of HNO with myoglobin and hemoglobin, 69, 116, 117 led to the assumption that HNO does not react with ferrous hemes. Kinetic analysis later suggested that the primary cellular targets for HNO are thiols and oxidized metals, while NO is thought to principally interact with other free radicals and with reduced metals. 91, 118 To explain the vasoactivity of HNO, the suggestion was made that HNO is converted to NO particularly in the aortic ring assays, for instance, by superoxide dismutase (SOD), metHb, and flavins 104 or by the release of normally sequestered species during tissue preparation. Furthermore, it may be that the addition of millimolar dithiothreitol (DTT), which is a vital stabilizing agent for sGC because of the oxidative instability of the heme and protein thiols under aerobic conditions, scavenged HNO before it could bind to the heme. This possibility in conjunction with the demonstration by Farmer and co-workers 16,17 of the thermally stable adduct of HNO with deoxymyoglobin led the Fukuto and Miranda laboratories to further investigate whether HNO can directly enhance the activity of sGC using bovine lung sGC purified in the Burstyn laboratory. Exposure of sGC to two structurally distinct HNO donors in thiol-free media led to a concentration-dependent increase in cGMP formation. 119 The extent of activation was lower than that from NO but was significantly elevated compared to basal levels. That sGC was not affected by a metal chelator but was modified by DTT clearly indicated that HNO can directly interact with sGC.
Both the heme and the multiple cysteine thiols of sGC are reasonable targets for HNO (Scheme 6). Removal of the heme decreased both HNO-and NO-mediated activity, supporting a direct interaction with the heme for both nitrogen oxides. Surprisingly, HNO did not activate ferric sGC, which was expected to undergo reductive nitrosylation to form the ferrous heme complex (eq 13).
Ferric sGC has been previously noted to be substitutionally inert to cyanide. 120 The impact of the reactivity of HNO with the protein thiols was investigated by substitution of the heme with the metal-free porphyrin, which activates the enzyme to a similar extent to the ferrous nitrosyl complex. 121 In this case, HNO decreased the activity, suggesting that cysteine thiols can function in a negative allosteric fashion when oxidized.
A second recent investigation 122 appeared to confirm 104 that HNO does not affect the sGC activity unless SOD is present. We suggest that, as with other studies that suggest the requirement for oxidation of HNO to NO, buffer components may be lead to unexpected scavenging of HNO. In addition to thiols, a N-(2-hydroxyethyl)-piperazine-N'-2-ethanesulfonic acid (HEPES) buffer has been shown previously to scavenge HNO, 83 and related agents such as triethylamine (TGA), which was used in the recent activity studies, may have a similar effect.
Conclusion. Exposure to HNO is known to affect a variety of thiol-containing proteins. That thermally stable complexes of HNO with heme proteins can now be readily produced suggests the possibility that metalloproteins may also be significant pharmacological targets for HNO. Because investigation of the chemical origin for the differing cardiovascular effects observed for HNO and NO donors in the studies by Paolocci et al. demonstrated that infusion of HNO did not result in a measurable increase in the plasma levels of cGMP, 91 questions remain about the role of HNO in whole organisms compared to in vitro assays or studies using excised tissues, which may have artifactual responses to HNO donors. Furthermore, whether HNO can activate sGC or coordinate to hemoglobin or myoglobin under Scheme 5. Activation of sGC upon Binding of NO to the Regulatory Heme
